Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.9 ILa | -1.98% | +10.00% | +182.86% |
Apr. 30 | XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Apr. 29 | Top Premarket Gainers | MT |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 8.814 | 7.005 | 15.68 | 14.99 | 6.363 | 5.28 |
Enterprise Value (EV) 1 | 0.6923 | 0.2773 | 9.639 | 8.867 | 2.642 | 3.274 |
P/E ratio | 2.95 x | -5.2 x | -20.1 x | 39.2 x | -4.72 x | -2.96 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -0.87 x | - | -10.2 x | -8.61 x | -3.01 x | -4.29 x |
EV / FCF | -1.44 x | -0.48 x | -19.4 x | -13.4 x | -4.77 x | -7.96 x |
FCF Yield | -69.3% | -207% | -5.15% | -7.45% | -21% | -12.6% |
Price to Book | 1.06 x | 1 x | 2.51 x | 2.83 x | 1.59 x | 2.38 x |
Nbr of stocks (in thousands) | 514,206 | 514,206 | 514,206 | 541,406 | 544,906 | 544,906 |
Reference price 2 | 0.0171 | 0.0136 | 0.0305 | 0.0277 | 0.0117 | 0.009690 |
Announcement Date | 3/11/19 | 3/12/20 | 3/15/21 | 3/30/22 | 3/22/23 | 4/30/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -0.792 | - | -0.947 | -1.03 | -0.879 | -0.764 |
EBIT 1 | -0.793 | -0.842 | -0.948 | -1.031 | -0.88 | -0.765 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | 2.986 | -1.347 | -0.782 | 0.435 | -1.348 | -1.782 |
Net income 1 | 2.986 | -1.347 | -0.782 | 0.435 | -1.348 | -1.782 |
Net margin | - | - | - | - | - | - |
EPS 2 | 0.005807 | -0.002619 | -0.001520 | 0.000706 | -0.002473 | -0.003270 |
Free Cash Flow 1 | -0.4796 | -0.5732 | -0.4965 | -0.6604 | -0.554 | -0.4111 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/11/19 | 3/12/20 | 3/15/21 | 3/30/22 | 3/22/23 | 4/30/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 8.12 | 6.73 | 6.04 | 6.13 | 3.72 | 2.01 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -0.48 | -0.57 | -0.5 | -0.66 | -0.55 | -0.41 |
ROE (net income / shareholders' equity) | 50% | -17.6% | -11.8% | 9.73% | -28.9% | -57.3% |
ROA (Net income/ Total Assets) | -6.54% | -6.67% | -8.64% | -9.82% | -10.2% | -14.5% |
Assets 1 | -45.67 | 20.2 | 9.051 | -4.429 | 13.24 | 12.32 |
Book Value Per Share 2 | 0.0200 | 0.0100 | 0.0100 | 0.0100 | 0.0100 | 0 |
Cash Flow per Share 2 | 0.0100 | 0.0100 | 0.0100 | 0.0100 | 0 | 0 |
Capex | - | 0 | 0 | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 3/11/19 | 3/12/20 | 3/15/21 | 3/30/22 | 3/22/23 | 4/30/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+182.86% | 14.99M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.62% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |
- Stock Market
- Equities
- XTLB Stock
- Financials XTL Biopharmaceuticals Ltd.